Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Santiago de Compostela (A Coruna), Spain Clinical Trials

A listing of Santiago de Compostela (A Coruna), Spain clinical trials actively recruiting patients volunteers.

Found (133) clinical trials

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must take one tablet with water every morning on …

Phase

1.26 miles

Learn More »

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Chemotherapy-nave patients high-intermediate TMB (TMB10 mutations/MB) and with locally advanced or metastatic non-squamous non-small cell lung cancer patients will be selected. Enroled patientswill receive 1200 mg of atezolizumab and 15mg/Kg of Avastin (bevacizumab) administered by IV infusion every 21 days (+/- 3 days). The treatment will start within 1-5 days …

Phase

1.26 miles

Learn More »

Study Investigating PK PD Efficacy Safety and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

This is a multicenter, randomized, parallel arm, double-blind study with a total duration up to 82 weeks. Approximately 522 postmenopausal patients with osteoporosis will be randomized at the beginning of Treatment Period 1 (Baseline to Week 52) to receive 2 doses of either GP2411 or EU-authorized Prolia. At the beginning …

Phase

1.26 miles

Learn More »

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) …

Phase

1.26 miles

Learn More »

Pivotal Study to Assess the Efficacy Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Approximately 68 weeks including a 4-week screening period, a 52-week treatment period, and 12 weeks of follow-up.

Phase

1.26 miles

Learn More »

Olaparib+Trastuzumab in HER2[+] Breast Cancer Susceptibility Gene (BRCA) Mutated or Homologous Recombination Deficient (HRD) Advanced Breast Cancer

This open-label, multicenter, single arm, two cohorts, Simon's Two-Stage minimax design, phase II clinical trial will assess the efficacy of olaparib in combination with trastuzumab in patients with HER2-positive ABC with gene alterations in HRR DNA pathway. To be included in the cohort A of the study, patients must exhibit …

Phase

1.26 miles

Learn More »

Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)

Approximately 400 eligible subjects will be randomized to one of the following 2 treatment arms Investigational Arm: Sacituzumab Govitecan 10 mg/kg via IV injection administered on Day 1 and Day 8 (21-day cycle). Control Arm: Recommended doses and schedules as per NCCN guidelines (with dose modifications if too toxic). Eribulin; …

Phase

1.26 miles

Learn More »

Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

- To determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias. - To determine the 2 and 3 year rate of locoregional disease control. - To evaluate the safety and toxicity of the combination of cetuximab and concomitant-boost accelerated …

Phase

1.26 miles

Learn More »

Prophylaxis With Caspofungin in High-Risk Liver Transplantation

This is a non-comparative, open, multisite prospective estimation study to evaluate the efficacy and safety of caspofungin in the prophylactic treatment of adults who have received an orthotopic liver transplant and are at high risk of developing an invasive fungal infection. It is expected that the proportion of high-risk liver …

Phase

1.26 miles

Learn More »

Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients

The PRESCO study (ribavirin dose 1000-1200 mg/day) emphasized that optimal ribavirin exposure seems to be crucial to maximize sustained virological response and minimize the incidence of relapses after treatment discontinuations. Recent reports showed that it is beneficial to extend the treatment duration in patients without rapid virological response at 4 …

Phase

1.26 miles

Learn More »